SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine
Active, not recruiting
- Conditions
- Dengue FeverDengue Hemorrhagic Fever
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2023-01-04
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 30000
- Registration Number
- NCT02948933
- Locations
- 🇲🇽
Investigational Site 2003-001, Puerto Vallarta, Mexico
🇲🇽Investigational Site 2004-001, Veracruz, Mexico
🇲🇽Investigational Site 2002-001, Monterrey, Mexico
Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
Completed
- Conditions
- Japanese Encephalitis
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 50
- Registration Number
- NCT02933710
- Locations
- 🇰🇷
001, Seoul, Korea, Republic of
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone Quadrivalent vaccine, No Preservative
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1950
- Registration Number
- NCT02915302
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No PreservativeBiological: Fluzone High-Dose, vaccine, 2016-2017 formulation
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 180
- Registration Number
- NCT02908269
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea
Phase 4
Completed
- Conditions
- Meningococcal InfectionsMeningitisMeningococcal Meningitis
- Interventions
- Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1311
- Registration Number
- NCT02864927
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
Phase 3
Completed
- Conditions
- MeningitisMeningococcal MeningitisMeningococcal Infections
- Interventions
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3344
- Registration Number
- NCT02842853
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older
Phase 3
Completed
- Conditions
- Meningococcal MeningitisMeningococcal InfectionsMeningitis
- Interventions
- Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate VaccineBiological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 907
- Registration Number
- NCT02842866
Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine
Completed
- Conditions
- Dengue FeverDengue Haemorrhagic Fever
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 334
- Registration Number
- NCT02827162
- Locations
- 🇹🇭
Investigational Site, Ratchaburi, Thailand
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Phase 2
Completed
- Conditions
- Dengue FeverDengue Hemorrhagic Fever
- Interventions
- Biological: Placebo, NaCl 0.9%Biological: CYD Dengue Vaccine (5 dose formulation)
- First Posted Date
- 2016-07-06
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 118
- Registration Number
- NCT02824198
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus InfectionDiphtheriaHepatitis BPertussisPolioTetanus
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 53
- Registration Number
- NCT02817451
© Copyright 2025. All Rights Reserved by MedPath